ICDM 2024

Research group on energy metabolism From beta cells to immune cells: new frontiers in metabolic disorders Chair(s): Cheol Soo Choi, SungHee Choi
Wednesday 09 October, 13:00~14:30
Room 1

Understanding energy metabolism is pivotal in the prevention and treatment of diabetes and related disorders. This session brings together leading researchers to present their latest findings and discuss their clinical implications. Key areas of focus include immune dysfunction and mitochondrial dysfunction, both hallmarks of metabolic disorders such as diabetes. Through their cutting-edge research, our three distinguished speakers will provide insights into novel prevention and treatment approaches that leverage advancements in energy metabolism. Join us to explore these new frontiers and their potential to transform the management of metabolic disorders.

RS1-1 Daisuke YabeKyoto University, Japan: SGLT2 inhibitors for older adults with type 2 diabetes: optimizing appropriate use

RS1-2 Kae Won ChoSoonchunhyang University, Korea: Role of obesogenic memory in obesity-related cardiovascular diseases

RS1-3 Hyeongseok KimChungnam National University, Korea: Mitochondrial dysfunction and pancreatic beta cell identity

Panel discussion

RS1-Panel 1
Joon Ho MoonSeoul National University, Korea
RS1-Panel 2
Jae-Han JeonKyungpook National University, Korea

Research group on beta cell biology and islet transplantation Islet function and mass: recent implications of variety stress and glucose metabolism Chair(s): Sung Hee Ihm, Kyu Chang Won
Wednesday 09 October, 13:00~14:30
Room 2

This session consists of a carefully chosen collection of lectures that aim to clarify the unknown mechanisms behind the mass and function of islets. Prof. Lori Sussel who is awarded Albert Renold Prize 2024 from EASD will provide new insights about beta cell maturation. Dr. Lee and Kim will present new perspectives on beta cell mass by stress, glucose metabolism, and gene expression control by chromatin accessibility.

RS2-1 Lori SusselUniversity of Colorado, USA: Altered RNA processing events in the diabetic islet

RS2-2 Joonyub LeeThe Catholic University of Korea, Korea: Multiparity increases the risk of diabetes by impairing the proliferative capacity of pancreatic β cells

RS2-3 Yong Kyung KimYeungnam University, Korea: Explores a novel mechanism of lactate mediated that has the potential to link the changes in glucose metabolism in beta cells

Research group on diabetic neuropathy Two underdiagnosed and undertreated complications of diabetic peripheral neuropathy: recent findings and unmet need Chair(s): Ie Byeong Park, Chong Hwa Kim
Wednesday 09 October, 13:00~14:30
Room 3

This session, titled "Two underdiagnosed and undertreated complications of diabetic peripheral neuropathy: recent findings and unmet needs", is a translational session designed to help clinicians understand the proper management of Diabetic Peripheral Neuropathy (DPN) in people with diabetes. DPN is a highly prevalent and disabling complication of diabetes that is often underdiagnosed and undertreated. In this session, we focus on the paradigm shift from treating DPN to early diagnosis, the role of the brain in DPN, and the comprehensive management strategies that still have a long way to go. The session features three speakers and three panelists, aiming to provide a better understanding of DPN management.

RS3-1 Tae Jung OhSeoul National University, Korea: How to shift the paradigm from treating DPN to diagnosing early?

RS3-2 Bin LuFudan University, China: Role of brain on diabetic neuropathic pain

RS3-3 Rodica Pop-BusuiUniversity of Michigan and Oregon Health Science University, USA: Comprehensive management of DPN: from optimal pain management to finding disease modifying therapies - a still a long way to go

Panel discussion

RS3-Panel 1
Ji Min KimChungnam National University, Korea
RS3-Panel 2
Eun Sook KimThe Catholic University of Korea, Korea
RS3-Panel 3
Seon Mee KangSoonchunhyang University, Korea

Research group on CGM and AID 1 Updates on CGM and AID Chair(s): Jae Hyeon Kim, Jae Hyoung Cho
Wednesday 09 October, 13:00~14:30
Room 5

This session offers a comprehensive exploration of the latest advancements in Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) systems. Discussions will focus on the concept of Time in Tight Range (TITR), specifically targeting the 70-140 mg/dL range, and will examine its relevance and applicability. Additionally, the session will introduce CGM-guided strategies for nutrition and exercise, along with novel algorithms that can detect unannounced meals and adjust insulin delivery accordingly.

RS4-1 Jee Hee YooChung-Ang University, Korea: Time in tight range (TITR) 70-140mg/dL: for whom and what?

RS4-2 Junhwan KimKakao Healthcare, Korea: CGM-guided nutrition and exercise: an introduction to PASTA, a new app for continuous glucose monitoring

RS4-3 So Yoon KwonDaegu Catholic University, Korea: Unannounced meal detection in recent insulin delivery systems

Panel discussion

RS4-Panel 1
Sang-Man JinSungkyunkwan University, Korea
RS4-Panel 2
Sun-Joon MoonSungkyunkwan University, Korea
RS4-Panel 3
Jun Sung MoonYeungnam University, Korea

Research group on fatty liver disease MASLD (MAFLD): from markers to clinical therapeutics Chair(s): Byung Wan Lee, You-Cheol Hwang
Wednesday 09 October, 14:40~16:10
Room 1

MASLD can be influenced by changes in energy metabolism and can also affect the onset of metabolic disorders. This session will explore these aspects by examining the association between ketogenesis and MASLD, as well as the risk of incident diabetes related to hepatic steatosis. We will then shift our focus to therapeutic approaches, comparing the effects of various antidiabetic drugs on MASLD, with particular attention to the metabolic impact of SGLT2 inhibitors, supported by recent therapeutic evidence.

RS5-1 Jaehyun BaeHallym University, Korea: Ketogenic capacity and MASLD (MAFLD)

RS5-2 Ji Cheol BaeSungkyunkwan University, Korea: Hepatic steatosis and the risk of type 2 diabetes

RS5-3 Won KimSeoul National University, Korea: Various oral antidiabetic drugs on MASLD

RS5-4 Se Hee MinUniversity of Ulsan, Korea: Therapeutic potential of SGLT2 inhibitors in MASLD

Research group on gestational diabetes Cutting edge research in gestational diabetes mellitus Chair(s): Moon-Suk Nam, Dong-Lim Kim
Wednesday 09 October, 14:40~16:10
Room 3

Gestational Diabetes Mellitus (GDM) is the most common complication during pregnancy, leading to adverse outcomes for both mother and child, both short-term and long-term. Numerous epidemiologic studies have demonstrated the risks associated with hyperglycemia during pregnancy, but the underlying mechanisms and potential interventions remain poorly understood. This session presents cutting-edge research on gestational diabetes mellitus, aiming to enhance understanding of GDM management and offer insights for future studies.

RS6-1 Arianne SweetingUniversity of Sydney, Australia: The role of CGM in diabetes in pregnancy

RS6-2 Marie-France HivertHarvard University, USA: Developmental origins of obesity and diabetes

RS6-3 Eunha KimKorea University, Korea: Type I IFN response at the placenta contributes to sex-biased neurodevelopmental outcome

RS6-4 Cathal McCarthyUniversity College Cork, Ireland: Evidence of defective visceral adipose tissue adaptation in Gestational Diabetes Mellitus

Research group on CGM and AID 2 Unmet guidelines - updates on CGM among non-intensive insulin treatment Chair(s): Keeho Song, Hun-Sung Kim
Wednesday 09 October, 14:40~16:10
Room 5

This session provides a comprehensive exploration of the unmet guidelines in Continuous Glucose Monitoring (CGM), presenting crucial updates and insights on its application across various scenarios for non-intensive insulin treatment. Attendees will gain valuable perspectives on the periodic use of CGM, optimal exercise strategies revealed by CGM, and the latest evidence supporting CGM in diverse patient populations, including prediabetes and obesity.

RS7-1 Sun-Joon MoonSungkyunkwan University, Korea: Unmet guidelines - periodic use of CGM among T2D

RS7-2 Yeoree YangThe Catholic University of Korea, Korea: Unmet guidelines - optimal exercise strategies revealed by CGM

RS7-3 Dughyun ChoiSoonchunhyang University, Korea: Unmet guidelines - current evidence of CGM in obesity and prediabetes

Panel discussion

RS7-Panel 1
Jun Hwa HongEulji University, Korea
RS7-Panel 2
Young Sang LyuChosun University, Korea

Research group on genetics Genetics of cardiovascular complications in diabetes Chair(s): Sung-Hoon Kim, Soo Heon Kwak
Wednesday 09 October, 16:20~17:50
Room 1

In this session, we will delve into the intricate genetic underpinnings linking diabetes and cardiovascular disease. Four distinguished speakers will present cutting-edge research on the genetic risk factors influencing these interconnected conditions. Among the highlights, we will explore the impact of polygenic scores and their interaction with diet, as well as investigate specific genetic risk factors for CVD in individuals with T2D.

RS8-1 Jordi MerinoUniversity of Copenhagen, Denmark: Polygenic scores, diet quality, and type 2 diabetes risk

RS8-2 Seung-Pyo LeeSeoul National University, Korea: Practical use of genetics to predict cardiovascular complications in high-risk population

RS8-3 Jaewon OhYonsei University, Korea: Clinical and translational experience of cardiovascular genetic clinic

RS8-4 Soo Heon KwakSeoul National University, Korea: Genetic risk factors for CVD in people with T2D

Research group on diabetic nephropathy Recent advances in diabetic kidney disease Chair(s): Nan Hee Kim, Tae Seo Sohn
Wednesday 09 October, 16:20~17:50
Room 3

Diabetic kidney disease is the leading cause of end-stage kidney disease, so much effort has been put into preventing its progression. As technology advances, new analysis methods and AI help us understand diabetic kidney disease. This session will introduce how to apply recent techniques to manage diabetic kidney disease and how close to precision medicine.

RS9-1 Jihwan ParkGIST, Korea: Chromatin accessibility analysis and architectural profiling of human kidneys reveal key cell types and a regulator of diabetic kidney disease

RS9-2 Ronald C.W. MaThe Chinese University of Hong Kong, China: Molecular epidemiology of diabetic kidney disease

RS9-3 Tyler Hyungtaek RimDuke-NUS Medical School, Singapore: Innovative AI solutions in retinal imaging: enhancing cardiovascular and kidney disease management

Panel discussion

RS9-Panel 1
Mi Kyung KimKeimyung University, Korea
RS9-Panel 2
Jin Joo ChaKorea University, Korea

Research group on diabetic vascular disease Integrated metabolic processes: exploring disease mechanisms and therapeutic targets Chair(s): Hyuk-Sang Kwon, Woo Je Lee
Wednesday 09 October, 16:20~17:50
Room 5

This session explores the intricate metabolic processes impacting diabetes and related diseases. Keynote presentations will cover the role of mitochondria metabolism in chorioretinal diseases, the significance of organ crosstalk through ketone body metabolism, and the metabolic reprogramming effects of SGLT2 inhibitors in isolated perfusion hearts. Join us to gain insights into novel therapeutic targets and mechanisms, which will enhance our understanding of integrated metabolic pathways and their potential to revolutionize diabetic care.

RS10-1 Junyeop LeeUniversity of Ulsan, Korea: Shaping endothelial window for maintaining metabolic homeostasis

RS10-2 Yuichiro ArimaKumamoto University, Japan: Organ crosstalk via ketone body metabolism

RS10-3 Hun-Jun ParkThe Catholic University of Korea, Korea: Metabolic reprogramming of SGLT2i in isolated perfusion hearts

Panel discussion

RS10-Panel 1
Jin Hwa KimChosun University, Korea
RS10-Panel 2
Mi Hae SeoSoonchunhyang University, Korea

Research group on development of new drug and technology on metabolic disease (K) The changing paradigm for research and development of new medicine and technology in metabolic disorder Chair(s): Choon Hee Chung, Jong Chul Won
Wednesday 09 October, 16:20~17:50
Grand hall 4

This session entitled ‘the changing paradigm for research and development of new medicine and technology in metabolic disorder’ is translational session and designed to provide a platform for clinicians and basic researchers on development of new drug and technology on metabolic disease to understand the novel pathogenesis and potential therapeutic targets for metabolic diseases. Topics will include the current status and strategies for drug development in Korea, the biotransformation era with its policy trends and R&D landscape, and the future perspectives on medical devices R&D in Korea. These discussions will enhance understanding of the recent advancement in novel drugs and technologies for metabolic diseases.

RS11-1 Yeong Min ParkKorea Drug Development Fund, Korea: How to collaborate with Korean R&D community

RS11-2 Doo-Byoung OhNational Research Foundation of Korea, Korea: Biotransformation era: policy trends and R&D landscape

RS11-3 Beop-Min KimKorea Medical Device Development Fund, Korea: Medical devices R&D in Korea and future perspectives

구분		사전등록 (~2024년 9월 2일까지)		현장등록 (2024년 10월 9일 ~ 11일)
구분		KDA회원	비회원	KDA회원	비회원
9~11일 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩280,000	₩350,000	₩370,000	₩450,000
9~11일 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩180,000	₩230,000	₩250,000	₩270,000
One-day 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩170,000	₩210,000	-
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩110,000	₩140,000	-
저녁 식사	전체	₩55,000

Program details

평점안내 (For Korean)